Carsyon 2 E Learning January
.jpg "Carsyon 2 E Learning January - Quiz")
Welcome to January E-Learning Test
Here is an opportunity to test your understanding of the topic given below:
Click the link : https://www.proprofs.com/training/course/? Title=landmark-trials
You have 20 minutes to complete this test once you have completed reading the topic.
Please enter your Name, Emp. Code, HQ and select your state and then press "Start" to begin the test. You can only attend the test once and hence make sure you have uninterrupted internet connectivity.
All the best
Micro Leadership Academy
Questions and Answers
- 1.
GUIDE Study compared which 2 sulphonylureas?
- A.
Gliclazide & Glimepride
- B.
Gliclazide & Glibenclamide
- C.
Gliclazide & Glipizide
- D.
Glipizide & Glimepride
Correct Answer
A. Gliclazide & GlimeprideExplanation
The correct answer is Gliclazide & Glimepride. The question is asking which two sulphonylureas were compared in the GUIDE Study.Rate this question:
-
- 2.
What was the reduction in heart attack seen with Rosuvastatin in JUPITER Trial?
- A.
54% reduction
- B.
45% reduction
- C.
50% reduction
- D.
48% reduction
Correct Answer
A. 54% reductionExplanation
Rosuvastatin, a statin medication, was found to have a 54% reduction in heart attack rates in the JUPITER Trial. This suggests that individuals who took Rosuvastatin experienced a significantly lower risk of heart attacks compared to those who did not take the medication. This finding highlights the potential effectiveness of Rosuvastatin in preventing heart attacks and supports its use as a preventative measure in individuals at risk for cardiovascular disease.Rate this question:
-
- 3.
The mortality and cardiovascular risk of various sufonylureas were compared with which drug in Danish Study
- A.
Gliptins
- B.
Metformin
- C.
Alpha glucosidase inhibitors
- D.
Insulin
Correct Answer
B. MetforminExplanation
The Danish Study compared the mortality and cardiovascular risk of various sulfonylureas with Metformin. This suggests that Metformin was chosen as the reference drug to evaluate the safety and efficacy of other sulfonylureas in terms of mortality and cardiovascular events.Rate this question:
-
- 4.
In LIFE study what was the reduction seen in new onset of diabetes?
- A.
25%
- B.
15%
- C.
13%
- D.
20%
Correct Answer
A. 25%Explanation
The LIFE study showed a reduction of 25% in the new onset of diabetes. This means that the study found a significant decrease in the number of participants who developed diabetes during the course of the study compared to those who did not participate. This reduction indicates that the intervention or treatment being studied in the LIFE study was effective in preventing or delaying the onset of diabetes.Rate this question:
-
- 5.
What was the duration of the Guide study?
- A.
16 weeks
- B.
20 weeks
- C.
27 weeks
- D.
12 weeks
Correct Answer
C. 27 weeksExplanation
The duration of the Guide study was 27 weeks.Rate this question:
-
- 6.
In Jupiter trial with Rosuvastatin, what the change seen hs- CRP at the end of 12 months
- A.
Reduced by 50 %
- B.
Reduced by 17 %
- C.
Reduced by 37 %
- D.
Reduced by 20 %
Correct Answer
C. Reduced by 37 %Explanation
The change seen in hs-CRP at the end of 12 months in the Jupiter trial with Rosuvastatin was a reduction of 37%.Rate this question:
-
- 7.
Which property of Gliclazide was highlighted in Danish study?
- A.
Cardiosafe
- B.
Renal Safe
- C.
Less chance of Hypoglycemia
- D.
Less chance of Hyperglycemia
Correct Answer
A. CardiosafeExplanation
The Danish study highlighted the property of Gliclazide being "Cardiosafe". This means that Gliclazide has a lower risk of causing adverse cardiovascular events compared to other medications. The study likely found that Gliclazide is a safer option for patients with cardiovascular issues, making it a preferred choice for managing diabetes in such individuals.Rate this question:
-
- 8.
What was the median followup with Rosuvastatin in the Jupiter trial after which the trial was stopped?
- A.
1.9 years
- B.
1.6 years
- C.
1.11 years
- D.
1.4 years
Correct Answer
A. 1.9 yearsExplanation
The correct answer is 1.9 years. This means that the median follow-up time with Rosuvastatin in the Jupiter trial was 1.9 years before the trial was stopped.Rate this question:
-
- 9.
In which reputed journal, was the Danish Study published?
- A.
Circulation
- B.
Diabetes Medicine
- C.
NEJM
- D.
European Heart Journal
Correct Answer
D. European Heart JournalExplanation
The Danish Study was published in the European Heart Journal, a reputable journal in the field of cardiology and cardiovascular medicine. This journal is known for publishing high-quality research articles related to heart health and disease. The European Heart Journal is widely recognized and respected within the medical community, making it a reliable source for scientific information in this field.Rate this question:
-
- 10.
Which property of Gliclazide was highlighted in GUIDE study?
- A.
Cardiosafe
- B.
Renal Safe
- C.
Less chance of Hypoglycemia
- D.
Less chance of Hyperglycemia
Correct Answer
C. Less chance of HypoglycemiaExplanation
The correct answer, "Less chance of Hypoglycemia," refers to a property of Gliclazide that was highlighted in the GUIDE study. This study likely found that Gliclazide has a lower risk of causing hypoglycemia, a condition characterized by abnormally low blood sugar levels, compared to other medications. This property makes Gliclazide a safer option for individuals with diabetes who are at risk of experiencing hypoglycemic episodes.Rate this question:
-
- 11.
How many patients finally enrolled after screening in Jupiter Trial
- A.
More than 17000 patients
- B.
More than 21000 patients
- C.
More than 29000 patients
- D.
More than 50000 patients
Correct Answer
A. More than 17000 patientsExplanation
The correct answer is more than 17000 patients. This means that after screening, the Jupiter Trial enrolled a total of more than 17000 patients.Rate this question:
-
- 12.
Number of patients in the Danish Study was
- A.
2 Lac
- B.
50000
- C.
1 Lacs
- D.
10000
Correct Answer
C. 1 LacsExplanation
The correct answer is 1 Lacs. This suggests that the number of patients in the Danish Study was 100,000.Rate this question:
-
- 13.
Incidences of pedal edema with combination of Losartan and Amlodipine in was how much fold lower than with Amlodipine monotherapy
- A.
6 fold
- B.
4 fold
- C.
2 fold
- D.
8 fold
Correct Answer
B. 4 foldExplanation
The incidence of pedal edema with the combination of Losartan and Amlodipine was 4 times lower compared to Amlodipine monotherapy. This suggests that the combination of Losartan and Amlodipine has a protective effect against pedal edema, reducing the occurrence of this side effect by 4 times compared to using Amlodipine alone.Rate this question:
-
- 14.
In ADVANCE study, what % of HbA1c goal was achieved with Gliclazide
- A.
7.5%
- B.
7%
- C.
6.5%
- D.
6%
Correct Answer
C. 6.5%Explanation
The correct answer is 6.5%. This implies that in the ADVANCE study, Gliclazide was able to achieve a HbA1c goal of 6.5%. This suggests that Gliclazide is effective in managing blood sugar levels and can help individuals with diabetes reach their target HbA1c levels.Rate this question:
-
- 15.
Name the study which shows better efficacy and tolerability of Losartan and Amlodipine combination
- A.
Life Study
- B.
Advance Study
- C.
Lothar Study
- D.
Road Map Study
Correct Answer
C. Lothar StudyExplanation
The Lothar Study is a study that demonstrates the superior effectiveness and tolerability of the combination of Losartan and Amlodipine. This study likely compared the combination therapy to other treatments or a placebo to determine its efficacy. The results of the study would have shown that the Losartan and Amlodipine combination is more effective and better tolerated than other options, making it a preferred treatment for the condition being studied.Rate this question:
-
- 16.
_________fewer hypoglycaemic episodes were with Gliclazide compared to Glimepiride in GUIDE Study
- A.
50%
- B.
40%
- C.
45%
- D.
60%
Correct Answer
A. 50%Explanation
In the GUIDE Study, it was found that Gliclazide had fewer hypoglycemic episodes compared to Glimepiride. The correct answer, 50%, suggests that the reduction in hypoglycemic episodes with Gliclazide was 50%. This means that there was a significant improvement in the management of hypoglycemia with Gliclazide as compared to Glimepiride, resulting in a 50% decrease in the occurrence of hypoglycemic episodes.Rate this question:
-
- 17.
How many patients received treatment with Gliclazide in ADVANCE study
- A.
More than 15000
- B.
More than 25000
- C.
More than 10,000
- D.
More than 1 Lac
Correct Answer
C. More than 10,000Explanation
The correct answer is "More than 10,000." This means that in the ADVANCE study, the number of patients who received treatment with Gliclazide was greater than 10,000.Rate this question:
-
- 18.
In LIFE study with which molecule was Losartan compared
- A.
Amlodipine
- B.
Ramipril
- C.
Atenolol
- D.
Telmisartan
Correct Answer
C. AtenololExplanation
In the LIFE study, Losartan was compared with Atenolol. The LIFE study was a clinical trial that aimed to compare the effectiveness of Losartan and Atenolol in reducing cardiovascular events in patients with hypertension. Atenolol is a beta-blocker medication commonly used to treat high blood pressure and reduce the risk of heart attacks and strokes. By comparing Losartan with Atenolol, the study aimed to determine which medication was more effective in preventing cardiovascular events in hypertensive patients.Rate this question:
-
- 19.
What was the mean HbA1c reduction observed with Gliclazide in GUIDE Study?
- A.
0.75%
- B.
1.2 %
- C.
1.5%
- D.
1%
Correct Answer
B. 1.2 %Explanation
The mean HbA1c reduction observed with Gliclazide in the GUIDE Study was 1.2%.Rate this question:
-
- 20.
What was the duration of Danish Study?
- A.
1 year
- B.
6 years
- C.
9 months
- D.
9 years
Correct Answer
D. 9 yearsExplanation
The Danish Study lasted for a duration of 9 years.Rate this question:
-
- 21.
__________% relative reduction in the risk of new or worsening nephropathy was observed with Gliclazide treatment in ADVANCE Study.
- A.
21%
- B.
23%
- C.
20%
- D.
25%
Correct Answer
A. 21%Explanation
In the ADVANCE Study, Gliclazide treatment was found to result in a 21% relative reduction in the risk of new or worsening nephropathy. This means that compared to the control group, the group receiving Gliclazide had a 21% lower risk of developing or worsening kidney disease. This suggests that Gliclazide may be an effective treatment option for reducing the risk of nephropathy.Rate this question:
-
- 22.
In Jupiter Trial, patients had high LDL levels but low hs- CRP
- A.
True
- B.
False
Correct Answer
B. FalseExplanation
The statement in the question states that patients in the Jupiter Trial had high LDL levels but low hs-CRP. However, the correct answer is false, which means that the statement is not true. This suggests that the patients in the Jupiter Trial did not have high LDL levels but low hs-CRP.Rate this question:
-
- 23.
Increased levels of inflammatory biomarker, hs-CRP predicts cardiovascular events
- A.
True
- B.
False
Correct Answer
A. TrueExplanation
Increased levels of the inflammatory biomarker hs-CRP have been shown to be a reliable predictor of cardiovascular events. Numerous studies have demonstrated a strong association between elevated hs-CRP levels and the risk of developing cardiovascular diseases such as heart attack and stroke. This biomarker reflects the presence of inflammation in the body, which is known to play a crucial role in the development and progression of cardiovascular diseases. Therefore, it is true that increased levels of hs-CRP can predict cardiovascular events.Rate this question:
-
- Academic Quizzes
- Adult Learning Quizzes
- Blended Learning Quizzes
- Career Quizzes
- Coaching Quizzes
- College Quizzes
- Communication Quizzes
- Curriculum Quizzes
- Distance Learning Quizzes
- Early Childhood Education Quizzes
- GCSE Quizzes
- Grade Quizzes
- Graduation Quizzes
- Online Exam Quizzes
- Online Test Quizzes
- Religious Education Quizzes
- School Quizzes
- Special Education Quizzes
- Student Quizzes
- Study Quizzes
- Subject Quizzes
- Teaching Quizzes
- Theory Quizzes
- Thesis Quizzes
- University Quizzes
Back to top